Pharmacological treatment of obesity in adults in Norway 2004–2022
Authors' conclusion
The use of anti-obesity drugs in Norway has increased substantially in recent years, especially among women aged 40 to 59 years. Changes in availability and reimbursement have influenced the use of these drugs in recent years.
Study context
- Population
- Adults aged 18–79 years in the Norwegian Prescribed Drug Register, 2004–2022
- Outcome
- Annual prevalence of anti-obesity drug use
- Follow-up
- 2004-2022
Methodological detailsregistry-based
- Registry-based
Main finding
As reported in the abstract
Prevalence of anti-obesity drug use in adult population · 2022
Bupropion-naltrexone (≥1 prescription filled); 72.8% women
1.04%
Liraglutide (Saxenda); 74.2% women
0.91%
Semaglutide without reimbursement; 76.7% women
0.68%
Observational data: associations, not effects.
Further findings
Initiation of anti-obesity drug treatment · 2017 to 2022
- Adult residents initiating treatment
- 2.8%
Total sale of anti-obesity drugs · 2017 to 2022
- 2017
- 1.1 million euros
- 2022
- 91.8 million euros
Original publication
Pharmacological treatment of obesity in adults in Norway 2004–2022. Diabetes Obes Metab. Published 28 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →